Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer

Molecular Carcinogenesis

Volumn 53, Issue 9, 2014, Pages 744-752

  Boulware, Stephen B ^a   Christensen, Laura A ^a   Thames, Howard ^b   Coghlan, Lezlee ^b   Vasquez, Karen M ^a   Finch, Rick A ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combination chemotherapy; DNA reactive agents; Oncogenes; Triplex forming oligonucleotides; Xenograft models

Indexed keywords

GEMCITABINE; NIBRIN; OLIGONUCLEOTIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DNA; MYC PROTEIN; MYC PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG EFFICACY; FEMALE; GENE TARGETING; HUMAN; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

MUS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; DEOXYCYTIDINE; DNA, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906240020     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22026     Document Type: Article

References (41)

1. American Cancer Society: Cancer Facts and Figures 2010. Atlanta: American Cancer Society; 2010.
2. Rockwell S, Grindey GB. Effect of 2′, 2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res 1992; 4:151-155.
3. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36:181-188.
4. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004; 4:177-183.
5. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999; 26:78-83.
6. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21:309-318.
7. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999; 26:71-77.
8. Cooney M, Czernuszewicz G, Postel EH, Flint SJ, Hogan ME. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 1988; 241:456-459.
9. Beal PA, Dervan PB. Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation. Science 1991; 251:1360-1363.
10. Christensen LA, Finch RA, Booker AJ, Vasquez KM. Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res 2006; 66:4089-4094.
11. Datta HJ, Chan PP, Vasquez KM, Gupta RC, Glazer PM. Triplex-induced recombination in human cell-free extracts. Dependence on XPA and HsRad51. J Biol Chem 2001; 276:18018-18023.
12. Rogers FA, Vasquez KM, Egholm M, Glazer PM. Site-directed recombination via bifunctional PNA-DNA conjugates. Proc Natl Acad Sci USA 2002; 99:16695-16700.
13. Wang G, Seidman MM, Glazer PM. Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 1996; 271:802-805.
14. Kim HG, Miller DM. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter. Biochemistry 1995; 34:8165-8171.
15. Postel EH, Flint SJ, Kessler DJ, Hogan ME. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci USA 1991; 88:8227-8231.
16. Thomas TJ, Faaland CA, Gallo MA, Thomas T. Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells. Nucleic Acids Res 1995; 23:3594-3599.
17. Kim H-G, Reddoch JF, Mayfield C, et al. Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex. Biochemistry 1998; 37:2299-2304.
18. Catapano CV, McGuffie EM, Pacheco D, Carbone GMR. Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene. Biochemistry 2000; 39:5126-5138.
19. Helm CW, Shrestha K, Thomas S, Shingleton HM, Miller DM. A unique c-myc-targeted triplex-forming oligonucleotide inhibits the growth of ovarian and cervical carcinomas in vitro. Gynecol Oncol 1993; 49:339-343.
20. Vasquez KM, Wang G, Havre PA, Glazer PM. Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Res 1999; 27:1176-1181.
21. Vasquez KM, Narayanan L, Glazer PM. Specific mutations induced by triplex-forming oligonucleotides in mice. Science 2000; 290:530-533.
22. Hertel LW, Kroin JS, Misner JW, Tustin JM. Synthesis of 2-deoxy-2, 2-difluoro-d-ribose and 2-deoxy-2, 2-difluoro-d-ribofuranosyl nucleotides. J Org Chem 1988; 53:2406-2409.
23. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23:3-15.
24. Crowther PJ, Cooper IA, Woodcock DM. Biology of cell killing by 1-beta-d-arabinofuranosylcytosine and its relevance to molecular mechanisms of cytotoxicity. Cancer Res 1985; 45:4291-4300.
25. Merriman RL, Hertel LW, Schultz RM, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 1996; 14:243-247.
26. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Gemcitabine in the treatment of advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2005; 17:425-429.
27. Rocha Lima CM, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR. Beyond pancreatic cancer: Irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol 2001; 28:34-43.
28. van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999; 80:981-990.
29. Robertson LE, Kantarjian H, O'Brien S, et al. Cisplatin, fludarabine, and ara-C (PFA): A regimen for advanced fludarabine-refractory chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 1993; 12:308.
30. Robertson LE, O'Brien S, Kantarjian H, et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9:943-945.
31. Keating MJ, O'Brien S, McLaughlin P, Kantarjian H, Cabanillas F. Fludarabine in combinations in the management of chronic lymphocytic leukemia and low grade lymphoma. Ann Oncol 1996; 7:34.
32. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14:1262-1268.
33. Zendegui JG, Vasquez KM, Tinsley JH, Kessler DJ, Hogan ME. In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res 1992; 20:307-314.
34. Kim HK, Kim JM, Kim SK, Rodger A, Norden B. Interactions of intercalative and minor groove binding ligands with triplex poly(dA).[poly(dT)]2 and with duplex poly(dA).poly(dT) and poly[d(A-T)]2 studied by CD, LD, and normal absorption. Biochemistry 1996; 35:1187-1194.
35. Mukherjee A, Vasquez KM. Triplex technology in studies of DNA damage, DNA repair, and mutagenesis. Biochimie 2011; 93:1197-1208.
36. Berkovich E, Monnat RJ, Jr., Kastan MB. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007; 9:683-690.
37. Harlow SP, Stewart CC. Quantitation of c-myc gene amplification by a competitive PCR assay system. PCR Methods Appl 1993; 3:163-168.
38. Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci USA 1983; 80:1707-1711.
39. Quinn LA, Moore GE, Morgan RT, Woods LK. Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res 1979; 39:4914-4924.
40. Gartel AL, Ye X, Goufman E, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98:4510-4515.
41. Wu Q, Gaddis SS, MacLeod MC, et al. High-affinity triplex-forming oligonucleotide target sequences in mammalian genomes. Mol Carcinog 2007; 46:15-23.